For women with postmenopausal osteoporosis at high risk for fracture
Proven to reduce the risk of fracture
A clinical study looked at how effective TYMLOS was at treating osteoporosis and reducing the risk of fracture in postmenopausal women:
- The study included over 1,600 postmenopausal women worldwide
- Women taking TYMLOS were compared with women taking a placebo (an injection that did not have any medicine)
- TYMLOS was taken for 18 months
The trial showed that at 18 months, women taking TYMLOS had:
Significantly lower risk of having a spinal fracture
Women taking TYMLOS had an 86% lower chance of getting a spinal fracture than those on placebo.
Your doctor might describe these spinal fractures as “compression fractures.”
These are the types of fractures that can cause women with postmenopausal osteoporosis to hunch.
(0.6% of women taking TYMLOS had a fracture vs 4.2% taking placebo.)
Lower risk of having fractures in other bones*
Compared with placebo, women taking TYMLOS had a 43% lower risk of non-spinal fractures.
(2.7% of women taking TYMLOS had a fracture compared to 4.7% of women taking placebo.)
*Fractures associated with high trauma were not included in the study, nor were fractures of the breast bone, kneecap, toes, fingers, skull or face.
Increased bone density
Women taking TYMLOS had significant increases in bone mineral density (BMD) in the spine and hip compared with women taking placebo.
At the start of the trial, women had the following average T-scores:
- Lumbar spine (lower back): -2.9
- Femoral neck (just below the ball joint of the hip): -2.1
- Total hip: -1.9
Women had the following average T-scores at 18 months:
- Lumbar spine (lower back): -2.1
- Femoral neck (just below the ball joint of the hip): -1.96
- Total hip: -1.63
Bone density is measured by a DXA scan. Ask your doctor if you need a DXA scan.
What happens after completing your TYMLOS treatment?
You and your doctor will discuss what is next in your treatment. In the clinical study, after patients took TYMLOS for 18 months they transitioned to alendronate, an oral generic bisphosphonate. Ask your doctor what is right for you.
Thank you to our participants
To everyone who took part in our clinical trials — from patient volunteers to doctors and nurses — thank you for your contributions that helped make this treatment available to women with postmenopausal osteoporosis!
And a special thanks to all the women who participated. You are truly OSTEOFEROCIOUS.
